SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-21-003757
Filing Date
2021-11-09
Accepted
2021-11-09 16:20:41
Documents
14
Period of Report
2021-11-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K inzy-20211109.htm   iXBRL 8-K 52277
2 EX-99.1 inzy-ex99_1.htm EX-99.1 150539
3 GRAPHIC img4202433_0.jpg GRAPHIC 8171
  Complete submission text file 0000950170-21-003757.txt   349024

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT inzy-20211109_lab.xml EX-101.LAB 14564
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT inzy-20211109_pre.xml EX-101.PRE 10675
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT inzy-20211109.xsd EX-101.SCH 2484
7 EXTRACTED XBRL INSTANCE DOCUMENT inzy-20211109_htm.xml XML 5110
Mailing Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210
Business Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210 857-330-4340
Inozyme Pharma, Inc. (Filer) CIK: 0001693011 (see all company filings)

IRS No.: 475129768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39397 | Film No.: 211392510
SIC: 2834 Pharmaceutical Preparations